Antibody drug conjugate (ADC) development
Antibody drug conjugates (ADCs) are an innovative biopharmaceuticals that combine the highly targeting specificity of antibodies with potent cytotoxic drug molecules linked through stable chemical linkers to provide superior therapeutic efficacy toward targeted diseases. ADC therapeutics comprise a new class of pharmaceuticals that provide both target specificity and therapeutic efficacy that may not be achieved by antibody or drug alone. Three are three major components in an effective ADC drug:
In past several decades, Nanocs has become an expert in ADC drug development. Our experience in the area of molecule synthesis, linker design and bioconjugation enables our customers to fully utilize our expertness in the development of their specific ADC drug candidates. Please fell free to contact us if you need any advice in your ADC drug development.
Related Products: SnapLink linkage agents
Cytotoxic agents for ADC development |